Important Classification Committee Update: Major Restructuring of ATC L-Class Impacting Oncology and Immunology.
The EPHMRA/Intellus ATC Classification Committee is embarking on a pivotal reorganisation of the L-class within the Anatomical Classification (ATC) system.
This significant change aims to better distinguish antineoplastic (oncology) therapies from immunological products, creating a clearer and more adaptable framework for emerging innovations in both therapeutic areas. Currently, oncology drugs and immunological products are grouped under the same ATC1 level (L-class).
While convenient in the past, this classification has become increasingly restrictive given the rapid development of novel therapies, particularly monoclonal antibodies (L1G) and protein kinase inhibitors (L1H). This grouping limits the availability of subcategories, making the classification less able to respond to market evolution.